Trial Profile
A study to evaluate the safety, tolerability, and immunogenicity of the Leish-111f + MPL-SE vaccine compared to the Leish-111f protein alone in Montenegro skin test-negative healthy adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs LEISH-F3 peptide vaccine (Primary) ; Monophosphoryl lipid A (Primary)
- Indications Cutaneous leishmaniasis; Leishmaniasis
- Focus Adverse reactions; Pharmacodynamics
- 24 Aug 2007 Status change
- 06 Dec 2005 New trial record.